TC
SUPN icon

Truvestments Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Truvestments Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-77
Closed -$2.75K – 914
2022
Q4 		$2.75K Hold
77
– – ﹤0.01% 667
2022
Q3 		$3K Hold
77
– – ﹤0.01% 527
2022
Q2 		$2K Buy
+77
New +$2.21K ﹤0.01% 577
2021
Q3 		– Sell
-100
Closed -$3K – 653
2021
Q2 		$3K Hold
100
– – ﹤0.01% 521
2021
Q1 		$3K Hold
100
– – ﹤0.01% 583
2020
Q4 		$2K Buy
+100
New +$2.15K ﹤0.01% 564

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Truvestments Capital's SUPN Position: Q1 2023 in Review

Truvestments Capital sold out of Supernus Pharmaceuticals (SUPN) in Q1 2023, closing a stake of 77 shares — an estimated $2.75K sold.

Truvestments Capital first reported a position in SUPN in Q4 2020 and held it in 6 quarters. The position peaked at $3K in Q3 2022. 258 funds tracked by Wall St. Rank hold SUPN as of Q1 2023.

  • Truvestments Capital reported no remaining Supernus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Truvestments Capital sold 77 Supernus Pharmaceuticals shares in Q1 2023, an estimated $2.75K.
  • Truvestments Capital first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Truvestments Capital's Supernus Pharmaceuticals position peaked at $3K in Q3 2022.
  • 258 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2023.

Based on Truvestments Capital's 13F filing for Q1 2023, filed 12 May 2023.